newsfilter
← Latest News
Business Wire·

Forte Biosciences Announces Pricing of $150 Million Public Offering

Forte Biosciences, Inc. (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a public offering of 5,709,936 shares of its common